Skip to content

Cytokine Storm Among Bangladeshi Patients With COVID-19

Investigating the Inflammatory Cytokines and Cytokine Storm Among Bangladeshi Patients With COVID-19: a Prospective, Observational Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04598334
Enrollment
75
Registered
2020-10-22
Start date
2022-07-15
Completion date
2022-12-31
Last updated
2022-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cytokine Storm, COVID-19

Keywords

Cytokine storm, COVID-19, Bangladesh

Brief summary

COVID -19, first reported in Wuhan, China, strikes the world hard as a pandemic by spreading up to 213 countries. Bangladesh is also facing its havoc with the death of 3000 among 229,185 cases at its 141st day. Most are mild cases presenting with influenza-like illness with expected recovery. According to World Health Organization, the overall global case fatality rate is currently estimated to be 2.9%. However, patients having severe or critical illness presenting with severe respiratory distress, ARDS or shock suffer most with mortality rates of 49.0-61.5%. Studies suggest that there are mild or severe cytokine storms in severe patients, which is an important cause of death. An exaggerated and uncontrolled release of pro-inflammatory mediators by an overly activated immune system is known as cytokine storms (CS) or cytokine release syndrome (CRS) which has an important role in the hemodynamic insults seen in very ill COVID-19 patients. This aberrant release of pro-inflammatory cytokines causes lung damage, myocarditis, acute kidney injury, etc. In this study, the investigators aim to estimate the burden of cytokines and their correlation with the magnitude of the severity of COVID-19 illness in Bangladeshi adults.

Detailed description

Background: 1. Burden: COVID -19, first reported in Wuhan, China, strikes the world hard as a pandemic by spreading up to 213 countries. Bangladesh is also facing its havoc with the death of 3000 among 229,185 cases at its 141st day. Most are mild cases presenting with influenza-like illness with expected recovery. According to World Health Organization, the overall global case fatality rate is currently estimated to be 2.9%. However, patients having severe or critical illness presenting with severe respiratory distress, ARDS or shock suffer most with mortality of 49.0-61.5%. Studies suggest that there are mild or severe cytokine storms in severe patients, which is an important cause of death. An exaggerated and uncontrolled release of proinflammatory mediators by an overly activated immune system is termed as cytokine storm (CS). Studies depicting that there might be an important relationship between SARS-CoV-2 and gut microbiota, as a marker to predict ARDS, can corroborate with the disease severity and outcomes of COVID-19. 2. Knowledge gap: Cytokine storm (CS) has an important role in the hemodynamic insults seen in very ill COVID-19 patients. In Bangladesh, no study has been conducted to evaluate the level of cytokines and the gut microbiota in COVID-19 patients presenting with different level of severity and their possible correlation with COVID-19. 3. Relevance: It will explore the role of CS and gut microbiota in COVID-19 illness severity. Thus, the results of the study will improve our knowledge and understanding of the problem, and thereby finding their solutions. Objectives: To estimate the burden of 'Cytokine Storm' and its correlation with the magnitude of the severity of COVID-19 illness in Bangladeshi adults. Methods: This will be a prospective observational study in adults aged ≥18 years old with COVID-19 having mild /moderate/severe/critical symptoms. The investigators will measure their cytokine (IL 6, TNF-Alpha, and IL1 Beta) levels and investigate gut microbiota in addition to regular laboratory tests at different time points of illness.

Interventions

None listed

Sponsors

International Centre for Diarrhoeal Disease Research, Bangladesh
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
Yes

Inclusion criteria

1. Adults aged ≥18 years, 2. Informed consent obtained for participation, 3. A mild, moderate or severe (±critical cases) RT-PCR confirmed COVID-19 cases, 4. RT-PCR negative healthy volunteers.

Design outcomes

Primary

MeasureTime frameDescription
COVID-19 positive participants having high cytokinesEight monthsThe proportion of COVID-19 positive participants having high cytokines during the study period

Secondary

MeasureTime frameDescription
High cytokine burden and severe COVID-19Eight monthsThe proportion of participants having both high cytokine burden and severe COVID-19 illness.

Other

MeasureTime frameDescription
Score on chest X-raySix monthsThe proportion of participants having a poor score on chest X-ray
Participants outcome as improved and discharged/referred/deteriorated/deathSix monthsParticipants outcome (improved & discharged/referred/deteriorated/death) as percentage
Three cytokines (IL-6, IL1β, TNF α) in healthy participantsEight monthsThe mean value of cytokines (IL-6, IL1β, TNF α) in healthy participants
Gut microbiotaEight monthsThe frequency distribution of different gut microbiota from stool specimen by 16S rRNA sequencing
Coagulation profileSix monthsThe proportion of participants having abnormal coagulation profile

Countries

Bangladesh

Contacts

Primary ContactMonira Sarmin, MBBS, MCPS
drmonira@icddrb.org+8801718596947
Backup ContactMohammod J Chisti, MBBS,PhD
chisti@icddrb.org

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026